Expert Interview
A Second Look: Discussing the results from Edgewise Therapeutics ARCH study of EDG-5506, a myofiber type II myosin inhibitor for patients with Becker Muscular Dystrophy (BMD).
Ticker(s): EWTXInstitution: University of Buffalo
- Clinical Associate Professor of Neurology at the University of Buffalo.
- Research is focused on several studies that address illnesses such as Guillain-Barre syndrome, myasthenia gravis and polyneuropathy.
- Basic science research is focused on pathophysiology of inherited neuropathies, which are known collectively as Charcot-Marie-Tooth (CMT) disease, with the goal of better understanding the underlying cause or mechanisms of these diseases.
Describe your background and practice setting
Added By: c_adminHow many patients with BMD do you manage?
Added By: c_adminWhat are your takeaways from the open label ARCH study of EDG-5506?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
